The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints von Vardhana, Santosha, Younes, Anas

Volltext

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial von Younes, Anas, Prof, Santoro, Armando, Prof, Shipp, Margaret, Prof, Zinzani, Pier Luigi, Prof, Timmerman, John M, MD, Ansell, Stephen, Prof, Armand, Philippe, MD, Fanale, Michelle, MD, Ratanatharathorn, Voravit, MD, Kuruvilla, John, MD, Cohen, Jonathon B, MD, Collins, Graham, MD, Savage, Kerry J, MD, Trneny, Marek, Prof, Kato, Kazunobu, MD, Farsaci, Benedetto, MD, Parker, Susan M, PhD, Rodig, Scott, MD, Roemer, Margaretha G M, MS, Ligon, Azra H, PhD, Engert, Andreas, Prof

Volltext

Brentuximab Vedotin (SGN-35) von Katz, Jessica, Janik, John E, Younes, Anas

Volltext

Emerging epigenetic-modulating therapies in lymphoma von Sermer, David, Pasqualucci, Laura, Wendel, Hans-Guido, Melnick, Ari, Younes, Anas

Volltext

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II... von Armand, Philippe, Engert, Andreas, Younes, Anas, Fanale, Michelle, Santoro, Armando, Zinzani, Pier Luigi, Timmerman, John M, Collins, Graham P, Ramchandren, Radhakrishnan, Cohen, Jonathon B, De Boer, Jan Paul, Kuruvilla, John, Savage, Kerry J, Trneny, Marek, Shipp, Margaret A, Kato, Kazunobu, Sumbul, Anne, Farsaci, Benedetto, Ansell, Stephen M

Volltext

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma von Younes, Anas, Sehn, Laurie H, Johnson, Peter, Zinzani, Pier Luigi, Hong, Xiaonan, Zhu, Jun, Patti, Caterina, Belada, David, Samoilova, Olga, Suh, Cheolwon, Leppä, Sirpa, Rai, Shinya, Turgut, Mehmet, Jurczak, Wojciech, Cheung, Matthew C, Gurion, Ronit, Yeh, Su-Peng, Lopez-Hernandez, Andres, Dührsen, Ulrich, Thieblemont, Catherine, Chiattone, Carlos Sergio, Balasubramanian, Sriram, Carey, Jodi, Liu, Grace, Shreeve, S Martin, Sun, Steven, Zhuang, Sen Hong, Vermeulen, Jessica, Staudt, Louis M, Wilson, Wyndham

Volltext

The Cantera: An Epic Learning Ring Cycle for Young Haematologists von Younes, Anas

Volltext

Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma von Matsuki, Eri, Younes, Anas

Volltext

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma von Roemer, Margaretha G M, Redd, Robert A, Cader, Fathima Zumla, Pak, Christine J, Abdelrahman, Sara, Ouyang, Jing, Sasse, Stephanie, Younes, Anas, Fanale, Michelle, Santoro, Armando, Zinzani, Pier Luigi, Timmerman, John, Collins, Graham P, Ramchandren, Radhakrishnan, Cohen, Jonathon B, De Boer, Jan Paul, Kuruvilla, John, Savage, Kerry J, Trneny, Marek, Ansell, Stephen, Kato, Kazunobu, Farsaci, Benedetto, Sumbul, Anne, Armand, Philippe, Neuberg, Donna S, Pinkus, Geraldine S, Ligon, Azra H, Rodig, Scott J, Shipp, Margaret A

Volltext

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma von YOUNES, Anas, GOPAL, Ajay K, FORERO-TORRES, Andres, MOSKOWITZ, Craig H, CONNORS, Joseph M, ENGERT, Andreas, LARSEN, Emily K, KENNEDY, Dana A, SIEVERS, Eric L, CHEN, Robert, SMITH, Scott E, ANSELL, Stephen M, ROSENBLATT, Joseph D, SAVAGE, Kerry J, RAMCHANDREN, Radhakrishnan, BARTLETT, Nancy L, CHESON, Bruce D, DE VOS, Sven

Volltext

Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review von COIFFIER, Bertrand, ALTMAN, Arnold, PUI, Ching-Hon, YOUNES, Anas, CAIRO, Mitchell S

Volltext

CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial von Oki, Yasuhiro, Kelly, Kevin R, Flinn, Ian, Patel, Manish R, Gharavi, Robert, Ma, Anna, Parker, Jefferson, Hafeez, Amir, Tuck, David, Younes, Anas

Volltext

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study von Younes, Anas, Dr, Connors, Joseph M, Prof, Park, Steven I, MD, Fanale, Michelle, MD, O'Meara, Megan M, MD, Hunder, Naomi N, MD, Huebner, Dirk, MD, Ansell, Stephen M, Prof

Volltext

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymp... von Younes, Anas, Prof, Thieblemont, Catherine, Prof, Morschhauser, Franck, Prof, Flinn, Ian, MD, Friedberg, Jonathan W, Prof, Amorim, Sandy, MD, Hivert, Benedicte, MD, Westin, Jason, MD, Vermeulen, Jessica, MD, Bandyopadhyay, Nibedita, PhD, de Vries, Ronald, MSc, Balasubramanian, Sriram, PhD, Hellemans, Peter, MD, Smit, Johan W, PhD, Fourneau, Nele, Oki, Yasuhiro, MD

Volltext

Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma von Gopal, Ajay K., Chen, Robert, Smith, Scott E., Ansell, Stephen M., Rosenblatt, Joseph D., Savage, Kerry J., Connors, Joseph M., Engert, Andreas, Larsen, Emily K., Chi, Xuedong, Sievers, Eric L., Younes, Anas

Volltext

Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting von He, Jie, Abdel-Wahab, Omar, Nahas, Michelle K., Wang, Kai, Rampal, Raajit K., Intlekofer, Andrew M., Patel, Jay, Krivstov, Andrei, Frampton, Garrett M., Young, Lauren E., Zhong, Shan, Bailey, Mark, White, Jared R., Roels, Steven, Deffenbaugh, Jason, Fichtenholtz, Alex, Brennan, Timothy, Rosenzweig, Mark, Pelak, Kimberly, Knapp, Kristina M., Brennan, Kristina W., Donahue, Amy L., Young, Geneva, Garcia, Lazaro, Beckstrom, Selmira T., Zhao, Mandy, White, Emily, Banning, Vera, Buell, Jamie, Iwanik, Kiel, Ross, Jeffrey S., Morosini, Deborah, Younes, Anas, Hanash, Alan M., Paietta, Elisabeth, Roberts, Kathryn, Mullighan, Charles, Dogan, Ahmet, Armstrong, Scott A., Mughal, Tariq, Vergilio, Jo-Anne, Labrecque, Elaine, Erlich, Rachel, Vietz, Christine, Yelensky, Roman, Stephens, Philip J., Miller, Vincent A., van den Brink, Marcel R.M., Otto, Geoff A., Lipson, Doron, Levine, Ross L.

Volltext

Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma von Mondello, Patrizia, Tadros, Saber, Teater, Matt, Fontan, Lorena, Chang, Aaron Y, Jain, Neeraj, Yang, Haopeng, Singh, Shailbala, Ying, Hsia-Yuan, Chu, Chi-Shuen, Ma, Man Chun John, Toska, Eneda, Alig, Stefan, Durant, Matthew, de Stanchina, Elisa, Ghosh, Sreejoyee, Mottok, Anja, Nastoupil, Loretta, Neelapu, Sattva S, Weigert, Oliver, Inghirami, Giorgio, Baselga, José, Younes, Anas, Yee, Cassian, Dogan, Ahmet, Scheinberg, David A, Roeder, Robert G, Melnick, Ari M, Green, Michael R

Volltext

Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma von Alperovich, Anna, Younes, Anas

Volltext

Tumor Lysis Syndrome and Acute Kidney Injury: Evaluation, Prevention, and Management von Abu-Alfa, Ali K., MD, Younes, Anas, MD

Volltext

Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial von Younes, Anas, Prof, Oki, Yasuhiro, MD, Bociek, R Gregory, MD, Kuruvilla, John, MD, Fanale, Michelle, MD, Neelapu, Sattva, MD, Copeland, Amanda, RN, Buglio, Daniela, MD, Galal, Ahmed, MD, Besterman, Jeffrey, PhD, Li, Zuomei, PhD, Drouin, Michel, MD, Patterson, Tracy, RN, Ward, M Renee, MD, Paulus, Jessica K, ScD, Ji, Yuan, PhD, Medeiros, L Jeffrey, Prof, Martell, Robert E, MD

Volltext